Prosthetic heart valve devices with tethered anchors and associated systems and methods

Information

  • Patent Grant
  • 11033390
  • Patent Number
    11,033,390
  • Date Filed
    Tuesday, March 5, 2019
    5 years ago
  • Date Issued
    Tuesday, June 15, 2021
    2 years ago
Abstract
Prosthetic heart valve devices with tethered anchors and associated systems and methods are disclosed herein. A heart valve device configured in accordance with embodiments of the present technology can include, for example, a valve support for carrying a prosthetic valve. The valve support can be configured to be implanted at an annulus of a native mitral valve. The device can further include at least one elongated flexible member extending from the valve support in a ventricular direction, and an anchor coupled to the valve support via the elongated flexible member. The anchor can be shaped to wrap around an exterior area of an apical portion of the heart. In addition, the anchor can inhibit retrograde migration of the valve support.
Description
TECHNICAL FIELD

The present technology relates generally to prosthetic heart valve devices. In particular, various embodiments of the present technology are related to prosthetic mitral valve devices with tethered anchors and associated methods and systems.


BACKGROUND

The mitral valve acts as a check valve to prevent flow of oxygenated blood back into the left atrium during systole, i.e., when the left ventricle contracts. This allows oxygenated blood to pump into the aorta through the aortic valve. Regurgitation of the mitral valve can significantly decrease the pumping efficiency of the heart and thereby increase the risk of severe, progressive heart failure. Mitral valve regurgitation can be characterized by retrograde flow from the left ventricle of a heart through an incompetent mitral valve into the left atrium. Mitral valve regurgitation can result from a number of mechanical defects. For example, leaflets, chordae tendineae coupled to the leaflets, and/or the papillary muscles of the mitral valve may be damaged or otherwise dysfunctional. In at least some instances, the mitral valve annulus itself may be damaged, dilated, or weakened such that the mitral valve does not close adequately during systole.


One mechanism for treating mitral valve regurgitation is mitral valve replacement. Percutaneous mitral valve replacement is significantly more challenging than aortic valve replacement because the native mitral valve and surrounding structures pose unique anatomical obstacles. Unlike the relatively symmetric and uniform native aortic valve, the mitral valve annulus has a non-circular, D-shape or kidney-like shape, with a non-planar saddle-like geometry. Such complexity makes it difficult to design a mitral valve prosthesis that conforms adequately to the mitral annulus to prevent leakage and backflow. For example, gaps between the prosthesis and the native tissue allow backflow of blood through the gaps from the left ventricle to the left atrium. As a result, cylindrical valve prostheses may leave gaps in commissural regions of the native valve that potentially result in perivalvular leaks in those regions.


In addition to its irregular, unpredictable shape, which changes size over the course of each heartbeat, the mitral valve annulus also lacks a significant amount of radial support from surrounding tissue. The aortic valve, for example, is completely surrounded by fibro-elastic tissue that provides the native structural support to anchor a prosthetic valve. The inner wall of the native mitral valve, however, is bound by a thin vessel wall separating the mitral valve annulus from the inferior portion of the aortic outflow tract. As a result, significant radial forces on the mitral annulus, such as those exerted by expanding stent prostheses, could cause collapse of the inferior portion of the aortic tract. Further, since the chordae tendineae extend from the papillary muscles to the underside of the leaflets, deploying a valve prosthesis on the ventricular side of the native mitral annulus is challenging. Thus, prosthetic mitral valves must accommodate the difficult anatomy of the mitral valve and surrounding structures.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. For ease of reference, throughout this disclosure identical reference numbers may be used to identify identical or at least generally similar or analogous components or features.



FIG. 1A is a partial cross-sectional side view of a heart valve device positioned in a heart in accordance with an embodiment of the present technology.



FIG. 1B is an enlarged cross-sectional view of a portion of the heart valve device of FIG. 1A.



FIGS. 2A-2C are partial cross-sectional side views illustrating stages of a trans-apical implantation procedure of a heart valve device in accordance with an embodiment of the present technology.



FIGS. 3A-3C are partial cross-sectional side views illustrating stages of a trans-septal implantation procedure of a heart valve device in accordance with an embodiment of the present technology.





DETAILED DESCRIPTION

The present technology is generally directed to prosthetic heart valve devices with tethered anchors and associated systems and methods. Specific details of several embodiments of the present technology are described herein with reference to FIGS. 1A-3C. Although many of the embodiments are described with respect to devices, systems, and methods for prosthetic heart valve devices for replacement of a native mitral valve, other applications and other embodiments in addition to those described herein are within the scope of the present technology. For example, at least some embodiments of the present technology may be useful for replacement of other valves, such as the tricuspid valve or the aortic valve. It should be noted that other embodiments in addition to those disclosed herein are within the scope of the present technology. Further, embodiments of the present technology can have different configurations, components, and/or procedures than those shown or described herein. Moreover, a person of ordinary skill in the art will understand that embodiments of the present technology can have configurations, components, and/or procedures in addition to those shown or described herein and that these and other embodiments can be without several of the configurations, components, and/or procedures shown or described herein without deviating from the present technology.


With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference relative positions of portions of a prosthetic valve device and/or an associated delivery device with reference to an operator and/or a location in the vasculature or heart. For example, in referring to a delivery catheter suitable to deliver and position various prosthetic valve devices described herein, “proximal” can refer to a position closer to the operator of the device or an incision into the vasculature, and “distal” can refer to a position that is more distant from the operator of the device or further from the incision along the vasculature (e.g., the end of the catheter). With respect to a prosthetic heart valve device, the terms “proximal” and “distal” can refer to the location of portions of the device with respect to the direction of blood flow. For example, proximal can refer to an upstream position or a position of blood inflow, and distal can refer to a downstream position or a position of blood outflow.



FIG. 1A is a partial cross-sectional side view of a heart valve device 100 (“device 100”) positioned in a heart H in accordance with an embodiment of the present technology, and FIG. 1B is an enlarged cross-sectional view of a portion of the device 100. As shown in FIG. 1A, the device 100 includes a valve support 102 for carrying a prosthetic valve 104 and a plurality of elongated flexible members (identified individually as first through fourth elongated flexible members 106a-106d, respectively; referred to collectively as elongated flexible members 106). The elongated flexible members 106 extend from the valve support 102 in a distal or ventricular direction. The device 100 further includes an anchor 108 coupled to the valve support 102 via the elongated flexible members 106. The anchor 108 can be shaped and sized to wrap around or otherwise at least substantially conform to an exterior area of an apical portion 101 of the heart H. The valve support 102 can be implanted at or proximate to an annulus A of a native mitral valve MV of the heart H, and the elongated flexible members 106 can extend from the valve support 102 in a ventricular direction through an opening 103 in the apical portion 101 of the heart wall 105 to the anchor 108. The elongated flexible members 106 can tether the valve support 102 to the anchor 108 such that the anchor 108 opposes movement of the valve support 102 in an atrial or proximal direction. Accordingly, the tethered anchor 108 inhibits retrograde migration of the valve support 102.


The device 100 can be compressible from an expanded or deployed state (shown in FIG. 1A) to low-profile, delivery state such that the device 100 can be delivered to a target site (e.g., the mitral valve MV). As discussed in further detail below, when in the low-profile delivery state, the device 100 can be constrained within a delivery catheter (not shown) that can, for example, trans-apically, transfemorally, or trans-septally deliver the device 100 to the target site. At the target site, the valve support 102 can deploy from the delivery catheter and transform to the larger, expanded state such that the valve support 102 engages native tissue at the target site, such as the native annulus A of the mitral valve MV, the leaflets L, and/or other tissue at the mitral valve MV. In various embodiments, the valve support 102 can self-expand to the expanded state. In other embodiments, the valve support 102 may be expanded using a balloon catheter or other stent-expansion devices. In other embodiments, the valve support 102 may be mechanically expandable.


The valve support 102 can be made from a stent or other type of frame that can carry the prosthetic valve 104. For example, valve support 102 can be made from a resilient biocompatible material that moves from the low-profile delivery state to the expanded state, such as stainless steel, platinum, nickel cobalt or cobalt chromium alloys (e.g., MP35N), nickel titanium alloys (e.g., Nitinol), and/or other suitable frame materials for carrying prosthetic valves. When the valve support 102 is made from superelastic shape memory materials, such as Nitinol, the valve support 102 can be collapsed into a very low profile delivery configuration suitable for delivery through the vasculature via a catheter (not shown), and self-expand when unconstrained from the catheter to a deployed configuration suitably sized to replace the target valve. The valve support can be a braided or woven frame, a laser-cut frame made from a metal tube, and/or other suitable stent structures.


The prosthetic valve 104 can include two, three, or more leaflets 110 that are arranged in a bicuspid, tricuspid, or other suitable valve configuration and attached to the valve support 102 using sutures, glue, and/or other suitable attachment mechanisms for joining the prosthetic valve 104 to the valve support 102. The leaflets 110 may be formed of various biocompatible, flexible, and at least substantially impermeable materials. For example, the leaflets 110 can be made from polytetrafluoroethylene (PTFE), polyethylene terephthalate, pyrolytic carbon, biologic tissue (e.g., pericardial tissue or xenograft valve tissue such as porcine heart tissue or bovine pericardium), and/or other biocompatible materials. During valve operation in a mitral application, the leaflets 110 move from a closed position in which blood flow is blocked from passing through the valve support 102 from the left ventricle to the left atrium and an open position in which blood flows through the valve support 102 in a downstream direction from the left atrium to the left ventricle. The valve support 102 can serve as a scaffold having radial rigidity to maintain a circular or other desired cross-sectional shape of the prosthetic valve 104 to ensure that the leaflets 110 coapt or otherwise seal when the device 100 is subject to external radial pressure (e.g., during systole). Suitable valve supports 102 and prosthetic valves 104 are described in, for example, U.S. patent application Ser. No. 13/664,652 to Duffy et al., filed Oct. 31, 2012; U.S. Pat. No. 8,323,336 to Hill et al., filed Apr. 23, 2009; PCT Patent Application No. PCT/US2012/043636 to Gifford et al., filed Jun. 21, 2012; PCT Patent Application No. PCT/US2012/061215 to Morriss et al., filed Oct. 19, 2012; PCT Patent Application No. PCT/US2012/061219 to Morriss et al., filed Oct. 19, 2012; and PCT Patent Application No. PCT/US2014/29549 to Morriss et al., filed Mar. 14, 2014. All of the foregoing applications and patents are incorporated herein by reference in their entireties.


The elongated flexible members 106 can be lines, tethers, chords, and/or other structures for connecting the valve support 102 to the anchor 108. In the embodiment illustrated in FIG. 1A, the device 100 includes four flexible members 106. In other embodiments, the device 100 can include one, two, three, or more than four flexible members 106. Each flexible member 106 shown in FIGS. 1A-1B includes a first end portion 112 attached to the valve support 102 and a second end portion 114 attached to the anchor 108. In other embodiments (note shown), the valve support 102 can be attached to a harness having one or more chords (e.g., three or four chords) that extend from the valve support 102 downwardly into the left ventricle and a single line that attaches the harness to the anchor 108. The first end portions 112 in the illustrated embodiment are independently attached to the valve support 102 at different, spaced apart portions of the valve support 102. For example, the first end portions 112 are spaced apart around the circumference or perimeter of the valve support 102. The first end portions 112 can be attached to a proximal region of the valve support 102 (e.g., near the left atrium LA), a central region of the valve support 102, a distal region of the valve support 102 (e.g., near the left ventricle LV), an outer side of the valve support 102, and/or to an inner side of the valve support 102. The first end portions 112 can be attached to individual struts of the valve support 102, intersections of struts of the valve support 102, a graft material associated with the valve support 102, and/or tether attachment loops or points on the valve support 102. Various attachment mechanisms can be used to attach the first end portions 112 to the valve support 102, such as tying the first end portions 112 to portions of the valve support 102, fastening the first end portions 112 to the valve support 102 using clips, tabs, clamps, and/or other fasteners, and/or gluing the first end portions to portions of the valve support. In further embodiments, the first end portions 112 of the elongated flexible members 106 can be attached to the leaflets 110. For example, the first end portions 112 can be drawn through the leaflets and fastened via sutures, tabs, and/or other suitable fastening mechanisms.


As shown in FIGS. 1A and 1B, the elongated flexible members 106 can extend from the valve support 102, through the left ventricle LV, and through the opening 103 in the heart wall 105 to where the second end portions 114 attach to the anchor 108. The second end portions 114 of the elongated flexible members 106 can be attached to the anchor 108 at a single attachment point on the anchor 108. As shown in FIG. 1B, in other embodiments the individual second end portions 114 of the elongated flexible members 106 can be attached at separate attachment regions (identified as first through fourth attachment regions 116a-116d, respectively; referred to collectively as attachment regions 116) spaced apart from each other on the anchor 108. These separate attachment regions 116 can facilitate distribution of the force applied by each of the elongated flexible members 106 across the anchor 108. The second end portions 114 can be attached to the anchor 108 using fasteners (e.g., clips, tabs, sutures, and/or glue), or the second end portions 114 may themselves be tied at the attachment regions 116.


The elongated flexible members 106 can be made from synthetic or harvested biocompatible materials. These materials may be selected such that they resist fatigue failure even after high numbers of cycles under which the flexible members 106 undergo relatively high levels of stress experienced during systole. Suitable materials for the elongated flexible members 106 may be elastic or inelastic, and may include biocompatible polymer materials, such as PTFE (polytetrafluoroethylene), polypropylene, ultra-high molecular weight polyethylene, nylon, silk, polyester, PVDF (polyvinylidene fluoride), and/or other suitable biocompatible materials.


In various embodiments, the elongated flexible members 106 may be adjustable in length such that the tension between the valve support 102 and the anchor 108 can be regulated. For example, the second end portions 114 of the elongated flexible members 106 can extend through a fastener at the anchor 108 that only allows movement in one direction (e.g., the proximal or distal direction). An operator can pull or push the second end portions 114 of the individual elongated flexible members 106 (extending through one or more fasteners) until the tension along each of the elongated flexible members 106 has reached a desired degree, and then the single-direction fastener can inhibit retraction of the elongated flexible member 106 toward the valve support 102. In other embodiments, the single-direction fasteners can also or alternatively be attached at the valve support 102. In further embodiments, one end portion of each of the elongated flexible members 106 can remain unattached to either the valve support 102 or the anchor 108, and the end portion can be tied-off or otherwise attached to the valve support 102 or the anchor 108 once the desired length is achieved. In still further embodiments, the elongated flexible members 106 can be non-adjustable and have pre-determined lengths. For example, the predetermined lengths of the elongated flexible members 106 can be determined based on the patient's anatomy before the device implantation procedure. In certain embodiments, the elongated flexible members 106 can each have a length of 2-8 cm. In other embodiments, the elongated flexible members 106 may be shorter than 2 cm or longer than 8 cm depending on the patient's anatomy and/or whether the elongated flexible members 106 are adjustable.


As shown in FIG. 1B, the anchor 108 can be made from a frame 118 and a non-permeable material 120 on the frame 118. In the illustrated embodiment, the non-permeable material 120 is on the interior portion of the frame 118. In other embodiments, however, the non-permeable material 120 can be attached to the exterior of the frame 118 or integrated with the frame 118. In further embodiments, the frame 118 itself can be non-permeable and/or the non-permeable material 120 may be omitted. The frame 118 can be a semi-rigid yet elastic or flexible structure, such as a basket, cage, mesh, mat or other structure made from braided materials, woven materials, linkages, and/or other semi-rigid structures that can maintain a generally convex or cup-like shape, while also being sufficiently flexible to conform to the apical portion 101 of the heart H during the dynamic heart cycle. For example, the frame 118 can be made from a self-expandable material (e.g., Nitinol), carbon and titanium alloys (e.g., Ti-6AL-4V), stainless steel, carbon fiber, and/or other suitable semi-rigid, biocompatible plastic or metal materials. The non-permeable material 120 can be made from a flexible, substantially nonporous material, such as polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), polypropylene, polyester, other graft materials, tissue (e.g., synthetic or animal pericardial tissue), and/or polyester.


The anchor 108, when expanded, has a concave interior surface area that curves around and generally conforms to the apical portion 101 of the heart H. In various embodiments, the anchor 108 can be attached to the apical portion 101 of the heart H via self-expansion by wrapping around the exterior surface of the apical portion 101 to secure itself to the heart H. In other embodiments, the anchor 108 may be attached to the apical portion 101 of the heart H via sutures and/or other suitable fasteners that join the anchor 108 to the heart H.


When secured in place, the anchor 108 and tethered connection to the valve support 102 counteract the retrograde forces applied to the valve support 102 during ventricular contraction. This prevents retrograde movement of the valve support 102 to maintain the desired position of the valve support 102 within the mitral valve MV. Because the anchor 108 stabilizes the valve support 102 and counters the force applied to the support 102 during systole, the valve support 102 itself must not include the same level of fixation structures and mechanisms that would be necessary to secure itself to the native annulus A as prosthetic heart valve devices that do not include the elongated flexible members 106 and the anchor 108. For example, the valve support 102 may have relatively small fixation area that contacts the native tissue (e.g., at the annulus A) and, therefore, facilitates the use of a smaller delivery catheter. In certain embodiments, for example, the proximal or superior portion of the valve support 102 does not extend above the native annulus.


The force imparted on the valve support 102 during systole and transferred to the anchor 108 by the elongated flexible members 106 can spread across the surface area of the anchor 108. This is expected to apply a less concentrated force to the anchor 108 and the opposing region of the heart wall 105 than if the elongated flexible members 106 were attached to a smaller fastener at a single point at the apical portion 101 of the heart H near the opening 103 in the heart wall 105. In certain embodiments, for example, the interior surface area of the anchor 108 (i.e., the surface area facing the apical portion 101 of the heart wall 105) can be several times greater than the area of the opening 103 in the heart wall 105 through which the elongated flexible members 106 extend. For example, the opening 103 in the heart wall 105 may be 18 Fr (6 mm in diameter), and the anchor 108 may have dimensions (e.g., an inner diameter or other cross-sectional dimension) corresponding to the dimensions of the apex of the patient's heart, which can vary from about 10 mm to 100 mm in diameter. Accordingly, the interior surface area of the anchor 108 can be two, three, five, ten, twenty, thirty, or more times larger than the opening 103. The anchor 108 is sized and shaped to conform to the three-dimensional curvature of the apex of the heart H such that the anchor 108 provides sufficient surface area to distribute the stresses applied to the anchor 108 by the elongated flexible members 106. Therefore, the anchor 108 can limit the degree of stress applied to the apical region 101 and to the ventricles and avoid damage to the opposing tissue of the heart wall 105.


The anchor 108 can also serve as a sealing mechanism that seals the opening 103 between in the heart wall 105 through which the elongated flexible members 106 extend. When the device 100 is implanted trans-apically, the opening 103 must be formed in the apical region 101 to deliver the device 100 to the mitral valve MV. Accordingly, the anchor 108 can be a substitute for purse string sutures or other closure mechanisms that are typically used to close the opening formed during trans-apical implantation procedures. In other embodiments, the opening 103 in the apical region 101 can be sutured or otherwise closed, and the anchor 108 can cover the closed opening 103.


In addition, the large basket-like structure of the anchor 108 supports the apical portion 101 of the heart and may thus inhibit expansion of the left ventricle LV. Patients that undergo mitral valve replacement often have progressive heart disease, which typically dilates (e.g., enlarges and/or lengthens) the left ventricle LV of the heart and expands the mitral valve MV such that the native leaflets no longer coapt. By wrapping around the apical portion 101 of the heart H and being semi-rigid, the anchor 108 also supports the apical portion 101 in its current state to reduce the likelihood of further expansion and maintain the ventricular structure. In further embodiments, the anchor 108 is configured to contract around the apical portion 101 to limit dilation and potentially decrease the size of the left ventricle LV.



FIGS. 2A-2C are side views illustrating stages of a trans-apical implantation procedure of the device 100 of FIGS. 1A and 1B in accordance with an embodiment of the present technology. The device 100 can be deployed using a delivery catheter 230, which can be controlled by an operator using a control apparatus (e.g., a handle; not shown) at a proximal portion (not shown) of the delivery catheter 230 outside of the patient. During a trans-apical delivery, the device 100 is compressed to a low-profile delivery state within a distal portion 232 of the delivery catheter 230, and the distal portion 232 delivery catheter 230 is inserted through the opening 103 into the left ventricle LV. As shown in FIG. 2A, once the distal end of the delivery catheter 230 is at the target site proximate to the annulus A of the mitral valve MV, the valve support 102 is released from the distal portion 232 of the delivery catheter 230 and expanded to a deployed state such that the valve support 102 contacts the native annulus A and/or surrounding tissue. The valve support 102 can self-expand to the deployed state or may be expanded using a balloon catheter and/or other type of expansion device.


After the valve support 102 is secured in position at the mitral valve MV, the delivery catheter 230 is retracted in a proximal direction (i.e., toward an operator, in a ventricular direction away from the mitral valve MV). As shown in FIG. 2B, as the delivery catheter 230 is withdrawn, the elongated flexible members 106 are deployed from the distal portion 232 of the delivery catheter 230 and through the opening 103 in the heart wall 105.


Upon exiting the opening 103, the anchor 108 is released from the delivery catheter 230 and expanded around the apical portion 101 of the heart. In various embodiments, the anchor 108 may self-expand around the exterior heart wall 105 to attach to the apical portion 101 of the heart. In other embodiments, the anchor 108 may be sutured or otherwise attached to the exterior heart wall 105. In embodiments where the anchor 108 is non-permeable, the anchor 108 can also seal the opening 103 (FIGS. 2A and 2B) in the heart wall 105 through which the device 100 was delivered to the mitral valve MV. In other embodiments, the opening 103 may be sutured or otherwise closed before or after deployment of the anchor 108. In embodiments where the elongated flexible members 106 are adjustable in length, the length of the flexible members 106 are adjusted, if needed, as the anchor 108 is deployed and/or after the anchor 108 has been deployed such that the flexible members 106 have the desired tautness between the valve support 102 and the anchor 108. After deployment, the anchor 108 inhibits retrograde movement or other migration of the valve support 102 by opposing forces applied to the valve support 102 during systole. The large, cup-like anchor 108 is expected to spread the forces applied to the anchor 108 by the elongated support members 106 across a relatively large surface area compared to a single-point tether connection, thereby reducing the force per area applied to the heart wall 105. Further, the conformal, cup-like anchor 108 may also support the apical portion 101 of the heart to stabilize and inhibit ventricular dilation as explained above.



FIGS. 3A-3C are side views illustrating stages of a trans-septal implantation procedure of the device 100 of FIGS. 1A and 1B in accordance with an embodiment of the present technology. Similar to the trans-apical delivery procedure discussed above with reference to FIGS. 2A-2C, the device 100 can be trans-septally deployed from a distal portion 332 of a delivery catheter 330 that is controlled using a control apparatus (e.g., a handle; not shown) at a proximal portion (not shown) of the delivery catheter 330 (outside of the patient). However, unlike the trans-apical delivery procedure, the trans-septal delivery can be performed intravascularly and the deployment of the device 100 occurs in generally the opposite order as the order of deployment during the trans-apical procedure. In this embodiment, the delivery catheter 330 is intravascularly delivered to the right atrium of the heart (e.g., via the aorta or the superior vena cava). A septal opening 307 is then formed in a septal wall 309 between the right and left atria such that the distal portion 332 of the delivery catheter 330 can be positioned in the left atrium.


As shown in FIG. 3A, the distal portion 332 of the delivery catheter 330 is passed through the mitral valve MV, into the left ventricle LV, and through an opening 303 formed in the apical portion 101 of the heart wall 105. The opening 303 in the apical portion 101 of the heart wall 105 and the septal opening 307 can be formed using various hole-forming devices (e.g., coring needles) coupled to the delivery catheter 330 and/or a separate device that is advanced before the distal portion 332 of the delivery catheter 330. Once the distal portion 332 of the delivery catheter 330 is positioned at the exterior of the heart wall 105, the anchor 108 can self-expand or otherwise deploy from the distal portion 332 around an exterior wall of the apical portion 101 of the heart. In this embodiment, the opening 303 may be smaller than the opening 103 (FIGS. 2A-2C) for trans-apical deployment because only the anchor 108 needs to be deployed through the opening 303, not the valve support 102 and the valve 104, which may have a larger cross-sectional dimension than the anchor 108. The deployed anchor 108 can seal the opening 303 created to deploy the anchor 108, or the opening 303 may be sutured or otherwise closed upon retraction of the delivery catheter 330 through the opening 303.


As the delivery catheter 330 retracts through the opening 303 into the left ventricle LV, the elongated flexible members 106 are released from the catheter 330 (FIG. 3B). At the target site proximate to the mitral valve MV, the valve support 102 is deployed from distal portion 332 of the delivery catheter 330 and expanded to an expanded or deployed state such that the valve support 102 is placed in apposition with the native annulus A and/or surrounding tissue of the mitral valve MV (FIG. 3C). In certain embodiments, the elongated flexible members 106 can be adjusted to provide a desired degree of tension between the anchor 108 and the valve support 102 such that the anchor 108 can inhibit retrograde movement of the valve support 102 during systole. After the device 100 is fully deployed, the delivery catheter 330 can retract into the left atrium LA and back through the opening 307, which can be sutured or otherwise closed before the delivery catheter 330 is withdrawn from the body.


Additional Examples

1. A heart valve device for implantation in a native mitral valve of a heart, the heart valve device comprising:

    • a valve support for carrying a prosthetic valve, wherein the valve support is configured to be implanted at an annulus of the native mitral valve;
    • at least one elongated flexible member extending from the valve support in a ventricular direction; and
    • an anchor coupled to the valve support via the elongated flexible member, wherein the anchor is shaped to wrap around an exterior area of an apical portion of the heart, and wherein the anchor is configured to inhibit retrograde migration of the valve support.


2. The heart valve device of example 1 wherein:

    • the elongated flexible member is configured to extend through an opening in the apical portion of the heart to connect to the anchor; and
    • the anchor comprises a material configured to cover and seal the opening in the apical portion of the heart.


3. The heart valve device of example 1 or 2 wherein the elongated flexible member comprises a first elongated flexible member and a second elongated flexible member, and wherein the first elongated flexible member connects to a first region of the anchor and the second elongated flexible member connects to a second region of the anchor spaced apart, the first region being spaced apart from the second region.


4. The heart valve device of any one of examples 1-3 wherein the elongated flexible member is a tether that restricts movement between the valve support and the anchor.


5. The heart valve device of any one of examples 1-4 wherein the anchor comprises a semi-rigid frame and a non-permeable material on the frame.


6. The heart valve device of any one of examples 1-5 wherein the anchor comprises a self-expandable frame having a conformal concave shape, the anchor being configured to self-expand to attach to the apical portion of the heart.


7. The heart valve device of any one of examples 1-6 wherein the anchor is sized and shaped to contract around the apical portion of the heart to lessen left ventricle dilation.


8. The heart valve device of any one of examples 1-7 wherein the anchor comprises a mesh basket configured to conform to the apical portion of the heart.


9. The heart valve device of any one of examples 1-8 wherein:

    • the valve support comprises a frame portion that supports the prosthetic valve; and
    • the elongated flexible member connects to the frame portion.


10. The heart valve device of any one of examples 1-8 wherein:

    • the valve support comprises a frame portion that supports the prosthetic valve;
    • the prosthetic valve comprises a plurality of leaflets; and
    • the elongated flexible member connects to one of the leaflets of the prosthetic valve.


11. The heart valve device of any one of examples 1-10 wherein the elongated flexible member is adjustable in length.


12. The heart valve device of example 1 wherein:

    • the valve support comprises a frame portion;
    • the elongated flexible member is one of a plurality of elongated flexible members connected to the frame portion at a plurality of spaced apart connection sites around a circumference of the frame portion;
    • the plurality of elongated flexible members are sized to extend from the frame portion through an opening in the apical portion of the heart to connect to the anchor; and
    • the anchor comprises a self-expandable material having a concave shape corresponding to the apical portion of the heart and configured to cover and seal the opening in the apical portion of the heart.


13. A heart valve device for implantation in a native valve of a heart, the heart valve device comprising:

    • a valve support configured to support a prosthetic valve;
    • an anchor having a surface area configured to attach and conform to an exterior portion of the heart downstream of the native valve; and
    • a plurality of elongated flexible members connecting the valve support to the anchor.


14. The heart valve device of example 13 wherein:

    • the valve support is sized and shaped to be implanted in a native annulus of a native mitral valve; and
    • the anchor is configured to attach to an apical portion of the heart proximate to a left ventricle of the heart.


15. The heart valve device of example 13 or 14 wherein the anchor comprises a self-expandable material, and wherein the anchor self-expands to a convex shape.


16. The heart valve device of any one of examples 13-15 wherein the elongated flexible members are flexible lines connected between the valve support and the anchor.


17. The heart valve device of any one of examples 13-16 wherein the anchor comprises a woven basket having a cup-shape configured to grip the apical portion of the heart.


18. A heart valve device for implantation in a native valve of a heart, the heart valve device comprising:

    • a valve support for carrying a prosthetic valve, wherein the annulus is configured to be implanted at an annulus of the native valve;
    • an anchor comprising a mesh structure having a concave shape when expanded, wherein the mesh structure is configured to conform to an exterior portion of an apical region of the heart; and
    • at least one elongated flexible member connecting the valve support to the anchor.


19. The heart valve device of example 18 wherein the mesh structure is made of nitinol.


20. A method of implanting a heart valve device in a native valve of a heart, the method comprising:

    • delivering, via a delivery catheter, the heart valve device to a chamber of the heart proximate to a native annulus of the native valve;
    • deploying a valve support from the delivery catheter into fixation against the native annulus;
    • deploying at least one elongated flexible member from the delivery catheter, wherein the elongated flexible member is connected to the valve support;
    • extending the elongated flexible member through an opening in a portion of the heart downstream of the native valve; and
    • deploying an anchor to conform around an exterior portion of the heart downstream of the native valve, wherein the anchor is configured to seal the opening in the heart and inhibit retrograde migration of the valve support.


21. The method of example 20 wherein deploying the valve support comprises affixing the valve support to the native annulus such that a superior portion of the valve support does not extend above the native annulus.


22. The method of example 20 or 21 wherein deploying the anchor comprises allowing the anchor to self-expand to a concave shape conforming to an exterior apical portion of the heart.


23. The method of any one of examples 20-22 wherein:

    • delivering the heart valve device to the chamber of the heart comprises trans-apically delivering the delivery catheter to a left ventricle of the heart;
    • deploying the valve support comprises affixing the valve support against the native annulus of a mitral valve of the heart; and
    • extending the elongated flexible member through the opening in the heart comprises extending the elongated flexible member through the same opening in the left ventricle of the heart used to deliver the delivery catheter to the left ventricle.


24. The method of any one of examples 20-22 wherein:

    • delivering the heart valve device to the chamber of the heart comprises trans-septally delivering the delivery catheter to a left ventricle of the heart; and
    • deploying the anchor occurs before deploying the valve support such that the delivery catheter is drawn in an upstream direction to expose the elongated flexible member and deploy the valve support.


25. The method of any one of examples 20-24, further comprising adjusting a length of the elongated flexible member such that the elongated flexible member is taut between the valve support and the anchor.


26. The method of any one of examples 20-25, further comprising supporting the exterior portion of the heart with the anchor to inhibit dilation of the exterior portion within the anchor.


27. A method of implanting a heart valve device in a native mitral valve of a heart, the method comprising:

    • delivering a delivery catheter across a septal wall of the heart into a chamber of the heart, wherein the delivery catheter contains a heart valve device;
    • forming an opening in an apical portion of the heart proximate to a left ventricle of the heart;
    • deploying, from the delivery catheter, an anchor at an exterior portion of the apical portion of the native mitral valve;
    • deploying at least one elongated flexible member from the delivery catheter, wherein the elongated flexible member extends from the anchor through the opening in the heart; and
    • deploying, from the delivery catheter, a valve support into fixation against a native annulus of the native mitral valve, wherein elongated flexible member extends between the valve support and the anchor, and the anchor is configured to inhibit retrograde migration of the valve support.


CONCLUSION

This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.


Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments.

Claims
  • 1. A method of implanting treating a native mitral heart valve of a heart, the method comprising: implanting a valve support at an annulus of the native mitral heart valve, wherein the valve support incudes a prosthetic valve having a plurality of leaflets, and wherein the valve support comprises a frame portion that supports the prosthetic valve;extending an elongated flexible member from the valve support through an opening in a left ventricle of an apical portion of the heart; anddeploying an anchor outside of the heart over the opening, wherein the anchor comprises a semi-rigid structure that conforms to an exterior area of the apical portion of the heart, wherein the anchor is coupled to the elongated flexible member to inhibit retrograde migration of the valve support, and wherein when deployed, the anchor is configured to wrap around the apical portion of the heart and inhibit expansion of the apical portion of the left ventricle,wherein deploying the anchor around the exterior area of the apical portion of the heart comprises allowing a self-expandable frame to expand to a concave shape that conforms to the exterior area during dynamic heart cycling.
  • 2. The method of claim 1 wherein the extending the elongated flexible member from the valve support comprises extending the elongated flexible member from one of the plurality of leaflets of the prosthetic valve.
  • 3. The method of claim 1, further comprising sealing the opening with a portion of the anchor.
  • 4. The method of claim 1, further comprising forming the opening in the left ventricle with a diameter of at most 6 mm, and wherein the anchor has a surface area at least three times that of the opening.
  • 5. The method of claim 1, further comprising adjusting a length of the elongated flexible member such that the elongated flexible member is taut between the valve support and the anchor.
  • 6. The method of claim 1, further comprising: delivering the valve support to the native mitral annulus via the opening in the left ventricle; anddeploying the valve support before deploying the anchor.
  • 7. The method of claim 1, further comprising: delivering the valve support and the anchor to the heart via an atrial septal opening; anddeploying the anchor before deploying the valve support.
  • 8. A method of treating a native mitral heart valve of a heart, the method comprising: implanting a valve support at an annulus of the native mitral heart valve, wherein the valve support incudes a prosthetic valve having a plurality of leaflets, and wherein the valve support comprises a frame portion that supports the prosthetic valve;extending a first elongated flexible member from the valve support through an opening in a left ventricle of an apical portion of the heart;extending a second elongated flexible member from the valve support through the opening in the apical portion of the heart; anddeploying an anchor outside of the heart over the opening, wherein the anchor comprises a semi-rigid structure that conforms to an exterior area of the apical portion of the heart, wherein a first region of the anchor is coupled to the first elongated flexible member and a second region of the anchor is coupled to the second elongated flexible member to inhibit retrograde migration of the valve support, and wherein when deployed, the anchor is configured to wrap around the apical portion of the heart and inhibit expansion of the apical portion of the left ventricle,wherein the first and second regions are spaced laterally apart from each other at opposing sides of the opening.
  • 9. A method of treating a native mitral heart valve of a heart, the method comprising: implanting a valve support at an annulus of the native mitral heart valve, wherein the valve support incudes a prosthetic valve having a plurality of leaflets, and wherein the valve support comprises a frame portion that supports the prosthetic valve;extending an elongated flexible member from the valve support through an opening in a left ventricle of an apical portion of the heart; anddeploying an anchor outside of the heart over the opening, wherein the anchor comprises a semi-rigid structure that conforms to an exterior area of the apical portion of the heart, wherein the anchor is coupled to the elongated flexible member to inhibit retrograde migration of the valve support, and wherein when deployed, the anchor is configured to wrap around the apical portion of the heart and inhibit expansion of the apical portion of the left ventricle,wherein deploying the anchor further comprises contracting the apical portion of the heart with the anchor to decrease ventricular dilation.
  • 10. The method of claim 9, further comprising delivering the valve support and the anchor to the annulus via a trans-septal approach through a septal opening.
  • 11. The method of claim 9, further comprising delivering the valve support to the annulus via a trans-apical approach through the opening in the apical portion of the heart.
  • 12. The method of claim 9 wherein the anchor comprises a frame with a conformal concave shape and a non-permeable material on the frame for sealing the opening.
  • 13. A method of treating a native heart valve of a heart, the method comprising: implanting a valve support at an annulus of the native heart valve, wherein the valve support comprises a frame portion configured to support a prosthetic valve comprising a plurality of leaflets;conforming an anchor around an exterior area of an apical portion of the heart by allowing a frame to self-expand to a concave structure that conforms to the apical portion of the heart during dynamic cycling; andextending a plurality of elongated flexible members from the valve support through an opening in the apical portion of the heart where the plurality of elongated flexible members attach to the anchor.
  • 14. The method of claim 13 wherein extending the plurality of elongated flexible members from the heart valve device comprises extending at least one of the elongated flexible members from a prosthetic leaflet carried by the valve support in a ventricular direction toward the anchor.
  • 15. The method of claim 13 wherein the frame has a surface area facing the heart, and the surface area is at least five times that of the opening in the apical portion of the heart.
  • 16. The method of claim 13 wherein the frame comprises a basket structure having a cup-shape and conforming the anchor around the exterior area of the heart comprises gripping the basket structure around the apical portion of the heart.
  • 17. The method of claim 13, further comprising tightening the elongated flexible members between the valve support and the anchor.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a Continuation of U.S. patent application Ser. No. 15/489,889, filed Apr. 18, 2017, now allowed, which claims priority to U.S. Provisional Patent Application No. 62/329,400, filed Apr. 29, 2016, both of which are incorporated by reference herein in their entireties.

US Referenced Citations (759)
Number Name Date Kind
3526219 Balamuth Sep 1970 A
3565062 Kuris Feb 1971 A
3589363 Banko Jun 1971 A
3667474 Lapkin et al. Jun 1972 A
3823717 Pohlman et al. Jul 1974 A
3861391 Antonevich et al. Jan 1975 A
3896811 Storz Jul 1975 A
4042979 Angell Aug 1977 A
4188952 Loschilov et al. Feb 1980 A
4431006 Trimmer et al. Feb 1984 A
4445509 Auth May 1984 A
4484579 Meno et al. Nov 1984 A
4490859 Black et al. Jan 1985 A
4587958 Noguchi et al. May 1986 A
4589419 Laughlin et al. May 1986 A
4602911 Ahmadi et al. Jul 1986 A
4646736 Auth Mar 1987 A
4692139 Stiles Sep 1987 A
4747821 Kensey et al. May 1988 A
4750902 Wuchinich et al. Jun 1988 A
4777951 Cribier et al. Oct 1988 A
4787388 Hofmann Nov 1988 A
4796629 Grayzel Jan 1989 A
4808153 Parisi Feb 1989 A
4819751 Shimada et al. Apr 1989 A
4841977 Griffith et al. Jun 1989 A
4870953 DonMicheal et al. Oct 1989 A
4878495 Grayzel Nov 1989 A
4898575 Fischell et al. Feb 1990 A
4909252 Goldberger Mar 1990 A
4919133 Chiang Apr 1990 A
4920954 Alliger et al. May 1990 A
4936281 Stasz Jun 1990 A
4960411 Buchbinder Oct 1990 A
4960424 Grooters Oct 1990 A
4986830 Owens et al. Jan 1991 A
4990134 Auth Feb 1991 A
5058570 Idemoto et al. Oct 1991 A
5069664 Guess et al. Dec 1991 A
5076276 Sakurai et al. Dec 1991 A
5106302 Farzin-nia et al. Apr 1992 A
5248296 Alliger Sep 1993 A
5267954 Nita Dec 1993 A
5269291 Carter Dec 1993 A
5295958 Shturman Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5314407 Auth et al. May 1994 A
5318014 Carter Jun 1994 A
5332402 Teitelbaum Jul 1994 A
5344426 Lau et al. Sep 1994 A
5344442 Deac Sep 1994 A
5352199 Tower Oct 1994 A
5356418 Shturman Oct 1994 A
5397293 Alliger et al. Mar 1995 A
5411025 Webster, Jr. et al. May 1995 A
5411552 Andersen et al. May 1995 A
5443446 Shturman Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5489297 Duran Feb 1996 A
5584879 Reimold et al. Dec 1996 A
5609151 Mulier et al. Mar 1997 A
5626603 Venturelli et al. May 1997 A
5656036 Palmaz Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5662704 Gross et al. Sep 1997 A
5681336 Clement et al. Oct 1997 A
5695507 Auth et al. Dec 1997 A
5725494 Brisken Mar 1998 A
5782931 Yang et al. Jul 1998 A
5817101 Fiedler Oct 1998 A
5827229 Auth et al. Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5853422 Huebsch et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5868781 Killion Feb 1999 A
5873811 Wang et al. Feb 1999 A
5904679 Clayman May 1999 A
5910129 Koblish et al. Jun 1999 A
5957882 Nita et al. Sep 1999 A
5972004 Williamson, IV et al. Oct 1999 A
5989208 Nita Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
6047700 Eggers et al. Apr 2000 A
6056759 Fiedler May 2000 A
6085754 Alferness et al. Jul 2000 A
6113608 Monroe et al. Sep 2000 A
RE36939 Tachibana et al. Oct 2000 E
6129734 Shturman et al. Oct 2000 A
6132444 Shturman et al. Oct 2000 A
6168579 Tsugita Jan 2001 B1
6217595 Shturman et al. Apr 2001 B1
6254635 Schroeder et al. Jul 2001 B1
6295712 Shturman et al. Oct 2001 B1
6306414 Koike Oct 2001 B1
6321109 Ben-haim et al. Nov 2001 B2
6332893 Mortier Dec 2001 B1
6402679 Mortier et al. Jun 2002 B1
6423032 Parodi Jul 2002 B2
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6494890 Shturman et al. Dec 2002 B1
6494891 Cornish et al. Dec 2002 B1
6505080 Sutton Jan 2003 B1
6530952 Vesely Mar 2003 B2
6540782 Snyders Apr 2003 B1
6562067 Mathis May 2003 B2
6565588 Clement et al. May 2003 B1
6569196 Vesely May 2003 B1
6579308 Jansen et al. Jun 2003 B1
6582462 Andersen et al. Jun 2003 B1
6595912 Lau et al. Jul 2003 B2
6605109 Fiedler Aug 2003 B2
6616689 Ainsworth et al. Sep 2003 B1
6623452 Chien et al. Sep 2003 B2
6638288 Shturman et al. Oct 2003 B1
6648854 Patterson et al. Nov 2003 B1
6689086 Nita et al. Feb 2004 B1
6702748 Nita et al. Mar 2004 B1
6730121 Ortiz et al. May 2004 B2
6746463 Schwartz Jun 2004 B1
6811801 Nguyen et al. Nov 2004 B2
6818001 Wulfman et al. Nov 2004 B2
6843797 Nash et al. Jan 2005 B2
6852118 Shturman et al. Feb 2005 B2
6855123 Nita Feb 2005 B2
6869439 White et al. Mar 2005 B2
6951571 Srivastava Oct 2005 B1
6986775 Morales et al. Jan 2006 B2
7018404 Holmberg et al. Mar 2006 B2
7052487 Cohn et al. May 2006 B2
7060021 Wilk Jun 2006 B1
7077861 Spence Jul 2006 B2
7125420 Rourke et al. Oct 2006 B2
7186264 Liddicoat et al. Mar 2007 B2
7261732 Justino Aug 2007 B2
7296577 Lashinski et al. Nov 2007 B2
7381218 Schreck Jun 2008 B2
7404824 Webler et al. Jul 2008 B1
7442204 Schwammenthal et al. Oct 2008 B2
7473275 Marquez Jan 2009 B2
7510575 Spenser et al. Mar 2009 B2
7585321 Cribier Sep 2009 B2
7588582 Starksen et al. Sep 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7708775 Rowe et al. May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753922 Starksen Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7803168 Gifford et al. Sep 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7896915 Guyenot et al. Mar 2011 B2
7942928 Webler et al. May 2011 B2
8002826 Seguin Aug 2011 B2
8052750 Tuval et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8109996 Stacchino et al. Feb 2012 B2
8114154 Righini et al. Feb 2012 B2
8226711 Mortier et al. Jul 2012 B2
8252051 Chau et al. Aug 2012 B2
8398704 Straubinger et al. Mar 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414643 Tuval et al. Apr 2013 B2
8449599 Chau et al. May 2013 B2
8496671 Hausen Jul 2013 B1
8512252 Ludomirsky et al. Aug 2013 B2
8518107 Tsukashima et al. Aug 2013 B2
8523883 Saadat Sep 2013 B2
8532352 Ionasec et al. Sep 2013 B2
8540767 Zhang Sep 2013 B2
8545551 Loulmet Oct 2013 B2
8551161 Dolan Oct 2013 B2
8579788 Orejola Nov 2013 B2
8579964 Lane et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8597347 Maurer et al. Dec 2013 B2
8597348 Rowe et al. Dec 2013 B2
8608796 Matheny Dec 2013 B2
8608797 Gross et al. Dec 2013 B2
8623077 Cohn Jan 2014 B2
8628566 Eberhardt et al. Jan 2014 B2
8632585 Seguin et al. Jan 2014 B2
8632586 Spenser et al. Jan 2014 B2
8634935 Gaudiani Jan 2014 B2
8647254 Callas et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8652204 Quill et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8672998 Lichtenstein et al. Mar 2014 B2
8673001 Cartledge et al. Mar 2014 B2
8679176 Matheny Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8688234 Zhu et al. Apr 2014 B2
8690858 Machold et al. Apr 2014 B2
8709074 Solem et al. Apr 2014 B2
8712133 Guhring et al. Apr 2014 B2
8715160 Raman et al. May 2014 B2
8721665 Oz et al. May 2014 B2
8721718 Kassab May 2014 B2
8740918 Seguin Jun 2014 B2
8747460 Tuval et al. Jun 2014 B2
8758431 Orlov et al. Jun 2014 B2
8758432 Solem Jun 2014 B2
8771292 Allen et al. Jul 2014 B2
8771345 Tuval et al. Jul 2014 B2
8771346 Tuval et al. Jul 2014 B2
8777991 Zarbatany et al. Jul 2014 B2
8778016 Janovsky et al. Jul 2014 B2
8781580 Hedberg et al. Jul 2014 B2
8784482 Randert et al. Jul 2014 B2
8792699 Guetter et al. Jul 2014 B2
8795356 Quadri et al. Aug 2014 B2
8801779 Seguin et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8808366 Braido et al. Aug 2014 B2
8812431 Voigt et al. Aug 2014 B2
8828043 Chambers Sep 2014 B2
8845717 Khairkhahan et al. Sep 2014 B2
8845723 Spence et al. Sep 2014 B2
8852213 Gammie et al. Oct 2014 B2
8852272 Gross et al. Oct 2014 B2
8858622 Machold et al. Oct 2014 B2
8859724 Meier et al. Oct 2014 B2
8864822 Spence et al. Oct 2014 B2
8870936 Rowe Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870949 Rowe Oct 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8894702 Quadri et al. Nov 2014 B2
8900295 Migliazza Dec 2014 B2
8926694 Costello Jan 2015 B2
8932348 Solem et al. Jan 2015 B2
8951285 Sugimoto et al. Feb 2015 B2
8961597 Subramanian et al. Feb 2015 B2
8968393 Rothstein Mar 2015 B2
8968395 Hauser et al. Mar 2015 B2
8974445 Warnking et al. Mar 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8979923 Spence et al. Mar 2015 B2
8986370 Annest Mar 2015 B2
8986376 Solem Mar 2015 B2
8992604 Gross et al. Mar 2015 B2
9011522 Annest Apr 2015 B2
9011523 Seguin Apr 2015 B2
9017399 Gross et al. Apr 2015 B2
9023098 Kuehn May 2015 B2
9023100 Quadri et al. May 2015 B2
9050188 Schweich, Jr. et al. Jun 2015 B2
9066800 Clague et al. Jun 2015 B2
9078749 Lutter et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095433 Lutter et al. Aug 2015 B2
9119713 Board et al. Sep 2015 B2
9125742 Yoganathan Sep 2015 B2
9132009 Hacohen et al. Sep 2015 B2
9138312 Tuval et al. Sep 2015 B2
9138313 McGuckin, Jr. et al. Sep 2015 B2
9180005 Lashinski et al. Nov 2015 B1
9192466 Kovalsky et al. Nov 2015 B2
9192471 Bolling Nov 2015 B2
9198756 Aklog et al. Dec 2015 B2
9232942 Seguin et al. Jan 2016 B2
9232999 Maurer et al. Jan 2016 B2
9241790 Lane et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9254192 Lutter et al. Feb 2016 B2
9271833 Kim et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9295547 Costello et al. Mar 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9308087 Lane et al. Apr 2016 B2
9326850 Venkatasubramanian May 2016 B2
9339378 Quadri et al. May 2016 B2
9339379 Quadri et al. May 2016 B2
9339380 Quadri et al. May 2016 B2
9339382 Tabor et al. May 2016 B2
9358108 Bortlein et al. Jun 2016 B2
9387075 Bortlein et al. Jul 2016 B2
9387078 Gross et al. Jul 2016 B2
9393111 Ma et al. Jul 2016 B2
9554906 Aklog et al. Jan 2017 B2
9610159 Christianson Apr 2017 B2
9629719 Rothstein et al. Apr 2017 B2
9681951 Ratz et al. Jun 2017 B2
9687342 Figulla et al. Jun 2017 B2
9687343 Bortlein et al. Jun 2017 B2
9693859 Braido et al. Jul 2017 B2
9693862 Campbell et al. Jul 2017 B2
9694121 Alexander et al. Jul 2017 B2
9700409 Braido et al. Jul 2017 B2
9700411 Klima et al. Jul 2017 B2
9730791 Ratz et al. Aug 2017 B2
9730792 Lutter Aug 2017 B2
9730794 Carpentier et al. Aug 2017 B2
9744036 Duffy et al. Aug 2017 B2
9750605 Ganesan et al. Sep 2017 B2
9750606 Ganesan et al. Sep 2017 B2
9750607 Ganesan et al. Sep 2017 B2
9763657 Hacohen et al. Sep 2017 B2
9763658 Eigler et al. Sep 2017 B2
9763782 Solem et al. Sep 2017 B2
9770328 Macoviak et al. Sep 2017 B2
9827092 Vidlund et al. Nov 2017 B2
9827101 Solem et al. Nov 2017 B2
9833313 Board et al. Dec 2017 B2
9833315 Vidlund et al. Dec 2017 B2
9839511 Ma et al. Dec 2017 B2
9844435 Eidenschink Dec 2017 B2
9848880 Coleman et al. Dec 2017 B2
9848983 Lashinski et al. Dec 2017 B2
9861477 Backus et al. Jan 2018 B2
9861480 Zakai et al. Jan 2018 B2
9895221 Vidlund et al. Feb 2018 B2
9986993 Vidlund Jun 2018 B2
10080659 Zentgraf et al. Sep 2018 B1
10085835 Thambar et al. Oct 2018 B2
10123874 Khairkhahan et al. Nov 2018 B2
10265172 Krivoruchko Apr 2019 B2
10610354 Vidlund Apr 2020 B2
10610356 Vidlund Apr 2020 B2
20010021872 Bailey et al. Sep 2001 A1
20010049492 Frazier et al. Dec 2001 A1
20020007219 Merrill et al. Jan 2002 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020072792 Burgermeister et al. Jun 2002 A1
20020077627 Johnson et al. Jun 2002 A1
20020082637 Lumauig Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020173841 Ortiz et al. Nov 2002 A1
20030078653 Vesely Apr 2003 A1
20030120340 Liska et al. Jun 2003 A1
20030139689 Shturman et al. Jul 2003 A1
20040006358 Wulfman et al. Jan 2004 A1
20040039412 Isshiki et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040057955 O'Brien et al. Mar 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092962 Thornton et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040106989 Wilson et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122510 Sarac Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040199191 Schwartz Oct 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230212 Wulfman Nov 2004 A1
20040230213 Wulfman Nov 2004 A1
20040243162 Wulfman Nov 2004 A1
20050007219 Ma et al. Jan 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075720 Pederson et al. Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050096647 Steinke et al. May 2005 A1
20050107661 Lau May 2005 A1
20050137682 Justino Jun 2005 A1
20050137690 Justino Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137700 Salahieh et al. Jun 2005 A1
20050137701 Spence et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050267523 Devellian et al. Dec 2005 A1
20060058872 Salahieh et al. Mar 2006 A1
20060106456 Machold et al. May 2006 A9
20060149360 Schwammenthal et al. Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20070056346 Spenser et al. Mar 2007 A1
20070061010 Hauser et al. Mar 2007 A1
20070073391 Bourang et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070161846 Nikolic Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070208217 Walsh Sep 2007 A1
20080071369 Tuval et al. Mar 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080103586 Styrc et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234728 Starksen et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20090048480 Klenk Feb 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090076586 Hauser et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090093670 Annest et al. Apr 2009 A1
20090157174 Yoganathan et al. Jun 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090259292 Bonhoeffer Oct 2009 A1
20090259306 Rowe Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276040 Rowe Nov 2009 A1
20090281609 Benichou et al. Nov 2009 A1
20090281618 Hill et al. Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090319038 Gurskis et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100023117 Yoganathan Jan 2010 A1
20100030330 Bobo et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100063586 Hasenkam et al. Mar 2010 A1
20100076548 Konno Mar 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100121436 Tuval et al. May 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249915 Zhang Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100298929 Thornton et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20100324554 Gifford et al. Dec 2010 A1
20110004296 Lutter Jan 2011 A1
20110015722 Hauser et al. Jan 2011 A1
20110022166 Dahlgren et al. Jan 2011 A1
20110029071 Zlotnick et al. Feb 2011 A1
20110029072 Gabbay Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110040375 Letac et al. Feb 2011 A1
20110066231 Cartledge et al. Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110112632 Chau et al. May 2011 A1
20110137397 Chau Jun 2011 A1
20110137409 Yang et al. Jun 2011 A1
20110137410 Hacohen Jun 2011 A1
20110153008 Marchand et al. Jun 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110184512 Webler et al. Jul 2011 A1
20110208293 Tabor Aug 2011 A1
20110208298 Tuval Aug 2011 A1
20110224785 Hacohen Sep 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20120022639 Hacohen et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120053680 Bolling et al. Mar 2012 A1
20120053682 Kovalsky et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101571 Thambar Apr 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179239 Quadri Jul 2012 A1
20120179244 Schankereli Jul 2012 A1
20120203336 Annest Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20130079873 Migliazza et al. Mar 2013 A1
20130172978 Vidlund Jul 2013 A1
20130190860 Sundt, III Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130197354 Maschke et al. Aug 2013 A1
20130197630 Azarnoush Aug 2013 A1
20130204356 Dwork et al. Aug 2013 A1
20130204358 Matheny Aug 2013 A1
20130226289 Shaolian et al. Aug 2013 A1
20130226290 Yellin et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130238089 Lichtenstein et al. Sep 2013 A1
20130244927 Lal et al. Sep 2013 A1
20130253641 Lattouf Sep 2013 A1
20130253642 Brecker Sep 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130259337 Guhring et al. Oct 2013 A1
20130261737 Costello Oct 2013 A1
20130261738 Clague et al. Oct 2013 A1
20130261739 Kuehn Oct 2013 A1
20130261741 Accola Oct 2013 A1
20130268066 Rowe Oct 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130282059 Ketai et al. Oct 2013 A1
20130282060 Tuval Oct 2013 A1
20130282110 Schweich, Jr. et al. Oct 2013 A1
20130289642 Hedberg et al. Oct 2013 A1
20130289717 Solem Oct 2013 A1
20130289718 Tsukashima et al. Oct 2013 A1
20130296851 Boronyak et al. Nov 2013 A1
20130296999 Burriesci et al. Nov 2013 A1
20130304180 Green et al. Nov 2013 A1
20130304181 Green et al. Nov 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304198 Solem Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130309292 Andersen Nov 2013 A1
20130310436 Lowes et al. Nov 2013 A1
20130310925 Eliasen et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130317603 McLean et al. Nov 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20130325114 McLean et al. Dec 2013 A1
20130331864 Jelich et al. Dec 2013 A1
20130338684 Hausen Dec 2013 A1
20130338763 Rowe et al. Dec 2013 A1
20130345797 Dahlgren et al. Dec 2013 A1
20130345803 Bergheim, III Dec 2013 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140018906 Rafiee Jan 2014 A1
20140018913 Cartledge et al. Jan 2014 A1
20140023261 Watanabe et al. Jan 2014 A1
20140025164 Montorfano et al. Jan 2014 A1
20140031928 Murphy Jan 2014 A1
20140046219 Sauter et al. Feb 2014 A1
20140046436 Kheradvar Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140052240 Zhang Feb 2014 A1
20140056906 Yue et al. Feb 2014 A1
20140066895 Kipperman Mar 2014 A1
20140067048 Chau et al. Mar 2014 A1
20140067052 Chau et al. Mar 2014 A1
20140067054 Chau et al. Mar 2014 A1
20140088071 Nakai et al. Mar 2014 A1
20140088680 Costello et al. Mar 2014 A1
20140088693 Seguin et al. Mar 2014 A1
20140088695 Figulla et al. Mar 2014 A1
20140094906 Spence et al. Apr 2014 A1
20140107775 Hjelle et al. Apr 2014 A1
20140114404 Gammie et al. Apr 2014 A1
20140114407 Rajamannan Apr 2014 A1
20140121763 Duffy et al. May 2014 A1
20140128965 Rafiee May 2014 A1
20140135913 Lichtenstein et al. May 2014 A1
20140163652 Witzel et al. Jun 2014 A1
20140163668 Rafiee Jun 2014 A1
20140172076 Jonsson et al. Jun 2014 A1
20140172084 Callas et al. Jun 2014 A1
20140172085 Quadri et al. Jun 2014 A1
20140172086 Quadri et al. Jun 2014 A1
20140179993 Alexander et al. Jun 2014 A1
20140180401 Rafiee Jun 2014 A1
20140188108 Goodine et al. Jul 2014 A1
20140188215 Hlavka et al. Jul 2014 A1
20140194920 Krahbichler Jul 2014 A1
20140194976 Starksen et al. Jul 2014 A1
20140200397 Raman et al. Jul 2014 A1
20140200649 Essinger et al. Jul 2014 A1
20140200657 Goodine et al. Jul 2014 A1
20140200662 Hlavka et al. Jul 2014 A1
20140214159 Vidlund Jul 2014 A1
20140219524 Takeguchi et al. Aug 2014 A1
20140222040 Park Aug 2014 A1
20140222138 Machold et al. Aug 2014 A1
20140228942 Krahbichler Aug 2014 A1
20140228946 Chau et al. Aug 2014 A1
20140242086 Lal et al. Aug 2014 A1
20140243860 Morris et al. Aug 2014 A1
20140243954 Shannon Aug 2014 A1
20140243964 Venkatasubramanian Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257101 Gaudiani Sep 2014 A1
20140257466 Board et al. Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140257473 Rajamannan Sep 2014 A1
20140257475 Gross et al. Sep 2014 A1
20140275757 Goodwin et al. Sep 2014 A1
20140276395 Wilson et al. Sep 2014 A1
20140276609 Magee et al. Sep 2014 A1
20140276782 Paskar Sep 2014 A1
20140276971 Kovach Sep 2014 A1
20140277119 Akpinar Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277404 Wilson et al. Sep 2014 A1
20140277405 Wilson et al. Sep 2014 A1
20140277406 Arcidi Sep 2014 A1
20140277407 Dale et al. Sep 2014 A1
20140277408 Folan Sep 2014 A1
20140277409 Bortlein et al. Sep 2014 A1
20140277410 Bortlein et al. Sep 2014 A1
20140277411 Bortlein et al. Sep 2014 A1
20140277412 Bortlein et al. Sep 2014 A1
20140277420 Migliazza et al. Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140288480 Zimmerman et al. Sep 2014 A1
20140296878 Oz et al. Oct 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140296970 Ekvall et al. Oct 2014 A1
20140296971 Tegels et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140303721 Fung et al. Oct 2014 A1
20140309727 Lamelas et al. Oct 2014 A1
20140309730 Alon et al. Oct 2014 A1
20140309731 Quadri et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316516 Vidlund et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140358222 Gorman, III et al. Dec 2014 A1
20140358224 Tegels Dec 2014 A1
20140364944 Lutter Dec 2014 A1
20140371843 Wilson et al. Dec 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140371846 Wilson et al. Dec 2014 A1
20140379074 Spence et al. Dec 2014 A1
20140379076 Vidlund Dec 2014 A1
20150005874 Vidlund Jan 2015 A1
20150005875 Tuval et al. Jan 2015 A1
20150025623 Granada et al. Jan 2015 A1
20150032127 Gammie et al. Jan 2015 A1
20150045878 Rowe Feb 2015 A1
20150057705 Vidlund Feb 2015 A1
20150066140 Quadri et al. Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150094803 Navia Apr 2015 A1
20150100116 Mohl et al. Apr 2015 A1
20150112427 Schweich, Jr. et al. Apr 2015 A1
20150112429 Khairkhahan et al. Apr 2015 A1
20150112433 Schweich, Jr. et al. Apr 2015 A1
20150119978 Tegels et al. Apr 2015 A1
20150119981 Khairkhahan et al. Apr 2015 A1
20150119982 Quill et al. Apr 2015 A1
20150127091 Cecere et al. May 2015 A1
20150127096 Rowe et al. May 2015 A1
20150142101 Coleman May 2015 A1
20150142103 Vidlund May 2015 A1
20150142105 Bolling et al. May 2015 A1
20150150678 Brecker Jun 2015 A1
20150157458 Thambar et al. Jun 2015 A1
20150157459 Macoviak et al. Jun 2015 A1
20150164637 Khairkhahan et al. Jun 2015 A1
20150164641 Annest Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150173898 Drasler et al. Jun 2015 A1
20150173900 Hauser et al. Jun 2015 A1
20150190229 Seguin Jul 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150202043 Zakai et al. Jul 2015 A1
20150209137 Quadri et al. Jul 2015 A1
20150209139 Granada et al. Jul 2015 A1
20150216655 Lane et al. Aug 2015 A1
20150216661 Hacohen et al. Aug 2015 A1
20150223802 Tegzes Aug 2015 A1
20150223934 Vidlund Aug 2015 A1
20150223935 Subramanian et al. Aug 2015 A1
20150230920 Alfieri et al. Aug 2015 A1
20150230921 Chau et al. Aug 2015 A1
20150238312 Lashinski Aug 2015 A1
20150238313 Spence et al. Aug 2015 A1
20150250461 Berreklouw Sep 2015 A1
20150250590 Gries et al. Sep 2015 A1
20150257877 Hernandez Sep 2015 A1
20150257878 Lane et al. Sep 2015 A1
20150257879 Bortlein et al. Sep 2015 A1
20150257881 Bortlein et al. Sep 2015 A1
20150257882 Bortlein et al. Sep 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150305861 Annest Oct 2015 A1
20150305864 Quadri et al. Oct 2015 A1
20150313739 Hummen et al. Nov 2015 A1
20150320553 Chau et al. Nov 2015 A1
20150327999 Board et al. Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150342733 Alkhatib et al. Dec 2015 A1
20150342737 Biancucci Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20150351908 Keranen et al. Dec 2015 A1
20150359628 Keranen Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20150359631 Sheahan et al. Dec 2015 A1
20150366666 Khairkhahan et al. Dec 2015 A1
20150374495 Ruyra Baliarda et al. Dec 2015 A1
20160000983 Mohl et al. Jan 2016 A1
20160015513 Lashinski et al. Jan 2016 A1
20160015514 Lashinski et al. Jan 2016 A1
20160015515 Lashinski et al. Jan 2016 A1
20160015543 Perouse et al. Jan 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160038246 Wang et al. Feb 2016 A1
20160038280 Morriss et al. Feb 2016 A1
20160038283 Divekar et al. Feb 2016 A1
20160038286 Yellin et al. Feb 2016 A1
20160074160 Christianson Mar 2016 A1
20160106539 Buchbinder et al. Apr 2016 A1
20160113764 Sheahan et al. Apr 2016 A1
20160113765 Ganesan et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160120643 Kupumbati May 2016 A1
20160143730 Kheradvar May 2016 A1
20160151154 Gorman, III et al. Jun 2016 A1
20160151156 Seguin et al. Jun 2016 A1
20160151552 Solem Jun 2016 A1
20160157999 Lane et al. Jun 2016 A1
20160158000 Granada et al. Jun 2016 A1
20160158001 Wallace et al. Jun 2016 A1
20160158002 Wallace et al. Jun 2016 A1
20160158003 Wallace et al. Jun 2016 A1
20160184095 Spence et al. Jun 2016 A1
20160206280 Vidlund et al. Jul 2016 A1
20160206424 Al-jilaihawi et al. Jul 2016 A1
20160213828 Sievers Jul 2016 A1
20160262881 Schankereli et al. Sep 2016 A1
20160317290 Chau et al. Nov 2016 A1
20160324635 Vidlund Nov 2016 A1
20170079790 Vidlund Mar 2017 A1
20170100248 Tegels et al. Apr 2017 A1
20170100250 Marsot et al. Apr 2017 A1
20170119526 Luong et al. May 2017 A1
20170128198 Cartledge et al. May 2017 A1
20170128205 Tamir et al. May 2017 A1
20170128206 Rafiee et al. May 2017 A1
20170128208 Christianson et al. May 2017 A1
20170156860 Lashinski Jun 2017 A1
20170165054 Benson et al. Jun 2017 A1
20170165055 Hauser et al. Jun 2017 A1
20170172737 Kuetting Jun 2017 A1
20170181851 Annest Jun 2017 A1
20170189179 Ratz et al. Jul 2017 A1
20170189180 Alkhatib Jul 2017 A1
20170189181 Alkhatib et al. Jul 2017 A1
20170231762 Quadri et al. Aug 2017 A1
20170231763 Yellin et al. Aug 2017 A1
20170258585 Marquez et al. Sep 2017 A1
20170266001 Vidlund et al. Sep 2017 A1
20170281345 Yang et al. Oct 2017 A1
20170290659 Ulmer et al. Oct 2017 A1
20170296339 Thambar et al. Oct 2017 A1
20170319333 Tegels Nov 2017 A1
20170325941 Wallace et al. Nov 2017 A1
20170325945 Dale et al. Nov 2017 A1
20170325948 Wallace et al. Nov 2017 A1
20170333186 Spargias Nov 2017 A1
20170333188 Carpentier et al. Nov 2017 A1
20170340440 Ratz et al. Nov 2017 A1
20170348098 Rowe et al. Dec 2017 A1
20170348100 Lane et al. Dec 2017 A1
20170354496 Quadri et al. Dec 2017 A1
20170354497 Quadri et al. Dec 2017 A1
20170354499 Granada et al. Dec 2017 A1
20170360426 Hacohen et al. Dec 2017 A1
20170360549 Lashinski et al. Dec 2017 A1
20170360558 Ma Dec 2017 A1
20170360585 White Dec 2017 A1
20180078370 Kovalsky Mar 2018 A1
20180289478 Quill Oct 2018 A1
20200179112 Vidlund Jun 2020 A1
Foreign Referenced Citations (342)
Number Date Country
1440261 Sep 2003 CN
101076290 Nov 2007 CN
101291637 Oct 2008 CN
103491900 Jan 2014 CN
19605042 Jan 1998 DE
102006052564 Dec 2007 DE
0186104 Jul 1986 EP
1512383 Mar 2005 EP
1545371 Jun 2005 EP
1551274 Jul 2005 EP
1629794 Mar 2006 EP
1646332 Apr 2006 EP
1702247 Sep 2006 EP
1734903 Dec 2006 EP
1891914 Feb 2008 EP
2026280 Feb 2009 EP
2037829 Mar 2009 EP
2081519 Jul 2009 EP
2111190 Oct 2009 EP
2142143 Jan 2010 EP
2167742 Mar 2010 EP
2278944 Feb 2011 EP
2306821 Apr 2011 EP
2327429 Jun 2011 EP
2400924 Jan 2012 EP
2400926 Jan 2012 EP
2410947 Feb 2012 EP
2444031 Apr 2012 EP
2488126 Aug 2012 EP
2509538 Oct 2012 EP
2549955 Jan 2013 EP
2549956 Jan 2013 EP
2566416 Mar 2013 EP
2586492 May 2013 EP
2618784 Jul 2013 EP
2623068 Aug 2013 EP
2626013 Aug 2013 EP
2629699 Aug 2013 EP
2633457 Sep 2013 EP
2637659 Sep 2013 EP
2641569 Sep 2013 EP
2644158 Oct 2013 EP
2654624 Oct 2013 EP
2656794 Oct 2013 EP
2656795 Oct 2013 EP
2656796 Oct 2013 EP
2667823 Dec 2013 EP
2670358 Dec 2013 EP
2676640 Dec 2013 EP
2688041 Jan 2014 EP
2697721 Feb 2014 EP
2713953 Apr 2014 EP
2714068 Apr 2014 EP
2723272 Apr 2014 EP
2723273 Apr 2014 EP
2723277 Apr 2014 EP
2739214 Jun 2014 EP
2741711 Jun 2014 EP
2750630 Jul 2014 EP
2750631 Jul 2014 EP
2755562 Jul 2014 EP
2755602 Jul 2014 EP
2757962 Jul 2014 EP
2777616 Sep 2014 EP
2777617 Sep 2014 EP
2782523 Oct 2014 EP
2785282 Oct 2014 EP
2786817 Oct 2014 EP
2790609 Oct 2014 EP
2793751 Oct 2014 EP
2809263 Dec 2014 EP
2810620 Dec 2014 EP
2814428 Dec 2014 EP
2814429 Dec 2014 EP
2819617 Jan 2015 EP
2819618 Jan 2015 EP
2819619 Jan 2015 EP
2416739 Feb 2015 EP
2833836 Feb 2015 EP
2838475 Feb 2015 EP
2839815 Feb 2015 EP
2844190 Mar 2015 EP
2849680 Mar 2015 EP
2849681 Mar 2015 EP
2852354 Apr 2015 EP
2870933 May 2015 EP
2873011 May 2015 EP
2875797 May 2015 EP
2760375 Jun 2015 EP
2882374 Jun 2015 EP
2886082 Jun 2015 EP
2886083 Jun 2015 EP
2886084 Jun 2015 EP
2895111 Jul 2015 EP
2901966 Aug 2015 EP
2907479 Aug 2015 EP
2945572 Nov 2015 EP
2948094 Dec 2015 EP
2948102 Dec 2015 EP
2964152 Jan 2016 EP
2967859 Jan 2016 EP
2967860 Jan 2016 EP
2967866 Jan 2016 EP
2968847 Jan 2016 EP
2981208 Feb 2016 EP
2982336 Feb 2016 EP
2999433 Mar 2016 EP
3003187 Apr 2016 EP
3003219 Apr 2016 EP
3003220 Apr 2016 EP
3010447 Apr 2016 EP
3013281 May 2016 EP
3017792 May 2016 EP
3021792 May 2016 EP
3023117 May 2016 EP
3027143 Jun 2016 EP
3033048 Jun 2016 EP
3037064 Jun 2016 EP
3229736 Nov 2016 EP
2470119 May 2017 EP
2999436 May 2017 EP
3184081 Jun 2017 EP
3191027 Jul 2017 EP
2611389 Aug 2017 EP
3082656 Aug 2017 EP
3206628 Aug 2017 EP
2010103 Sep 2017 EP
2509538 Sep 2017 EP
3223751 Oct 2017 EP
3027144 Nov 2017 EP
3110368 Nov 2017 EP
3110369 Nov 2017 EP
3132773 Nov 2017 EP
3245980 Nov 2017 EP
3250154 Dec 2017 EP
3256077 Dec 2017 EP
3258883 Dec 2017 EP
3273910 Jan 2018 EP
H06504516 May 1994 JP
H10258124 Sep 1998 JP
2002509756 Apr 2002 JP
2005280917 Oct 2005 JP
2008528117 Jul 2008 JP
2008541863 Nov 2008 JP
2009195712 Sep 2009 JP
2010518947 Jun 2010 JP
5219518 Jun 2013 JP
WO1992017118 Oct 1992 WO
WO1995016407 Jun 1995 WO
WO1999004730 Feb 1999 WO
WO1999039648 Aug 1999 WO
WO1999049799 Oct 1999 WO
WO2001010343 Feb 2001 WO
WO2002003892 Jan 2002 WO
WO2002028421 Apr 2002 WO
WO2002039908 May 2002 WO
WO2003043685 May 2003 WO
WO2004084746 Oct 2004 WO
WO2004093728 Nov 2004 WO
WO2004096097 Nov 2004 WO
WO2004112657 Dec 2004 WO
WO2005002466 Jan 2005 WO
WO2005007219 Jan 2005 WO
WO2005009285 Feb 2005 WO
WO2005009506 Feb 2005 WO
WO2005087140 Sep 2005 WO
WO2006041877 Apr 2006 WO
WO2006063199 Jun 2006 WO
WO2007008371 Jan 2007 WO
WO2007067820 Jun 2007 WO
WO2008022077 Feb 2008 WO
WO2008028569 Mar 2008 WO
WO2008035337 Mar 2008 WO
WO2008103497 Aug 2008 WO
WO2008103722 Aug 2008 WO
WO2008129405 Oct 2008 WO
WO2009045338 Apr 2009 WO
WO2009091509 Jul 2009 WO
WO2010006627 Jan 2010 WO
WO2010008549 Jan 2010 WO
WO2010057262 May 2010 WO
WO2010080594 Jul 2010 WO
WO2010098857 Sep 2010 WO
WO2010099032 Sep 2010 WO
WO2010117680 Oct 2010 WO
WO2010121076 Oct 2010 WO
WO2011025981 Mar 2011 WO
WO2011047168 Apr 2011 WO
WO2011051043 May 2011 WO
WO2011057087 May 2011 WO
WO2011072084 Jun 2011 WO
WO2011106137 Sep 2011 WO
WO2011106544 Sep 2011 WO
WO2011111047 Sep 2011 WO
WO2011137531 Nov 2011 WO
WO2011139747 Nov 2011 WO
WO2012011018 Jan 2012 WO
WO2012011108 Jan 2012 WO
WO2012027487 Mar 2012 WO
WO2012035279 Mar 2012 WO
WO2012040655 Mar 2012 WO
WO2012047644 Apr 2012 WO
WO2012052718 Apr 2012 WO
WO2012055498 May 2012 WO
WO2012087842 Jun 2012 WO
WO2012095455 Jul 2012 WO
WO2012102928 Aug 2012 WO
WO2012106602 Aug 2012 WO
WO2012118508 Sep 2012 WO
WO2012118816 Sep 2012 WO
WO2012118894 Sep 2012 WO
WO2012177942 Dec 2012 WO
WO2013021374 Feb 2013 WO
WO2013021375 Feb 2013 WO
WO2013028387 Feb 2013 WO
WO2013059743 Apr 2013 WO
WO2013059747 Apr 2013 WO
WO2013114214 Aug 2013 WO
WO2013120181 Aug 2013 WO
WO2013123059 Aug 2013 WO
WO2013128432 Sep 2013 WO
WO2013130641 Sep 2013 WO
WO2013131925 Sep 2013 WO
WO2013140318 Sep 2013 WO
WO2013148017 Oct 2013 WO
WO2013148018 Oct 2013 WO
WO2013148019 Oct 2013 WO
WO2013150512 Oct 2013 WO
WO2013152161 Oct 2013 WO
WO2013158613 Oct 2013 WO
WO2013169448 Nov 2013 WO
WO2013175468 Nov 2013 WO
WO2013176583 Nov 2013 WO
WO2013188077 Dec 2013 WO
WO2013192107 Dec 2013 WO
WO2014036113 Mar 2014 WO
WO2014043527 Mar 2014 WO
WO2014047111 Mar 2014 WO
WO2014047325 Mar 2014 WO
WO2014055981 Apr 2014 WO
WO2014059432 Apr 2014 WO
WO2014064694 May 2014 WO
WO2014066365 May 2014 WO
WO2014089424 Jun 2014 WO
WO2014093861 Jun 2014 WO
WO2014111918 Jul 2014 WO
WO2014114794 Jul 2014 WO
WO2014114795 Jul 2014 WO
WO2014114796 Jul 2014 WO
WO2014114798 Jul 2014 WO
WO2014116502 Jul 2014 WO
WO2014121280 Aug 2014 WO
WO2014128705 Aug 2014 WO
WO2014134277 Sep 2014 WO
WO2014138194 Sep 2014 WO
WO2014138284 Sep 2014 WO
WO2014138482 Sep 2014 WO
WO2014138868 Sep 2014 WO
WO2014144100 Sep 2014 WO
WO2014144937 Sep 2014 WO
WO2014145338 Sep 2014 WO
WO2014147336 Sep 2014 WO
WO2014152306 Sep 2014 WO
WO2014152375 Sep 2014 WO
WO2014152503 Sep 2014 WO
WO2014153544 Sep 2014 WO
WO2014158617 Oct 2014 WO
WO2014162181 Oct 2014 WO
WO2014162306 Oct 2014 WO
WO2014163705 Oct 2014 WO
WO2014168655 Oct 2014 WO
WO2014179391 Nov 2014 WO
WO2014181336 Nov 2014 WO
WO2014189974 Nov 2014 WO
WO2014191994 Dec 2014 WO
WO2014194178 Dec 2014 WO
WO2014201384 Dec 2014 WO
WO2014201452 Dec 2014 WO
WO2014205064 Dec 2014 WO
WO2014207699 Dec 2014 WO
WO2014210124 Dec 2014 WO
WO2014210299 Dec 2014 WO
WO2015009503 Jan 2015 WO
WO2015020971 Feb 2015 WO
WO2015028986 Mar 2015 WO
WO2015051430 Apr 2015 WO
WO2015052663 Apr 2015 WO
WO2015057407 Apr 2015 WO
WO2015057735 Apr 2015 WO
WO2015057995 Apr 2015 WO
WO2015061378 Apr 2015 WO
WO2015061431 Apr 2015 WO
WO2015061463 Apr 2015 WO
WO2015061533 Apr 2015 WO
WO2015075128 May 2015 WO
WO2015081775 Jun 2015 WO
WO2015089334 Jun 2015 WO
WO2015092554 Jun 2015 WO
WO2015120122 Aug 2015 WO
WO2015125024 Aug 2015 WO
WO2015127264 Aug 2015 WO
WO2015127283 Aug 2015 WO
WO2015191604 Aug 2015 WO
WO2015191839 Aug 2015 WO
WO2015195823 Aug 2015 WO
WO2016011185 Aug 2015 WO
WO2015128739 Sep 2015 WO
WO2015128741 Sep 2015 WO
WO2015128747 Sep 2015 WO
WO2015132667 Sep 2015 WO
WO2015132668 Sep 2015 WO
WO2015135050 Sep 2015 WO
WO2015142648 Sep 2015 WO
WO2015142834 Sep 2015 WO
WO2016020918 Sep 2015 WO
WO2016027272 Sep 2015 WO
WO2016059533 Sep 2015 WO
WO2016065158 Sep 2015 WO
WO2016073741 Sep 2015 WO
WO2016083551 Sep 2015 WO
WO2016093877 Sep 2015 WO
WO2015148241 Oct 2015 WO
WO2015171190 Nov 2015 WO
WO2015171743 Nov 2015 WO
WO2015179181 Nov 2015 WO
WO2015184452 Dec 2015 WO
WO2016097337 Jun 2016 WO
WO2016108181 Jul 2016 WO
WO2016133950 Aug 2016 WO
WO2017062640 Apr 2017 WO
WO2017096157 Jun 2017 WO
WO2017100927 Jun 2017 WO
WO2017101232 Jun 2017 WO
WO2017117388 Jul 2017 WO
WO2017127939 Aug 2017 WO
WO2017136596 Aug 2017 WO
WO2017196511 Nov 2017 WO
WO2017196909 Nov 2017 WO
WO2017196977 Nov 2017 WO
WO2017197064 Nov 2017 WO
WO2017218671 Dec 2017 WO
WO2018017886 Jan 2018 WO
Non-Patent Literature Citations (48)
Entry
US 9,265,606 B2, 02/2016, Buchbinder et al. (withdrawn)
Bernard et al., “Aortic Valve Area Evolution After Percutaneous Aortic Valvuloplasty,” European Heart Journal, Jul. 1990, vol. 11 (2), pp. 98-107.
BlueCross BlueShield of Northern Carolina Corporate Medical Policy “Balloon valvuloplasty, Percutaneous”, (Jun. 1994).
Cimino et al., “Physics of Ultrasonic Surgery Using Tissue Fragmentation: Part I and Part II”, Ultrasound in Medicine and Biologyl, Jun. 1996, vol. 22 (1), pp. 89-100, and pp. 101-117.
Cimino, “Ultrasonic Surgery: Power Quantification and Efficiency Optimization”, Aesthetic Surgery Journal, Feb. 2001, pp. 233-241.
Cowell et al., “A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis,” NEJM, Jun. 2005, vol. 352 (23), pp. 2389-2397.
De Korte et al., “Characterization of Plaque Components and Vulnerability with Intravascular Ultrasound Elastography”, Phys. Med. Biol., Feb. 2000, vol. 45, pp. 1465-1475.
European Search Report dated Mar. 13, 2015 for European Application. No. 05853460.3.
Feldman, “Restenosis Following Successful Balloon Valvuloplasty: Bone Formation in Aortic Valve Leaflets”, Cathet Cardiovasc Diagn, May 1993, vol. 29 (1), pp. 1-7.
Fitzgerald et al., “Intravascular Sonotherapy Decreased Neointimal Hyperplasia After Stent Implantation in Swine”, Circulation, Feb. 2001, vol. 103, pp. 1828-1831.
Freeman et al., “Ultrasonic Aortic Valve Decalcification: Serial Doppler Echocardiographic Follow Up”, J Am Coll Cardiol., Sep. 1990, vol. 16 (3), pp. 623-630.
Greenleaf et al., “Selected Methods for Imaging Elastic Properties of Biological Tissues”, Annu. Rev. Biomed. Eng., Apr. 2003, vol. 5, pp. 57-78.
Gunn et al., “New Developments in Therapeutic Ultrasound-Assisted Coronary Angioplasty”, Curr Intery Cardiol Rep., Dec. 1990, vol. 1 (4), pp. 281-290.
Guzman et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius”, Ultrasound in Med. & Biol., Mar. 2003, vol. 29 (8), pp. 1211-1222.
Hallgrimsson et al., “Chronic Non-Rheumatic Aortic Valvular Disease: a Population Study Based on Autopsies”, J Chronic Dis., Jun. 1979, vol. 32 (5), pp. 355-363.
Isner et al., “Contrasting Histoarchitecture of Calcified Leaflets from Stenotic Bicuspid Versus Stenotic Tricuspid Aortic Valves”, J Am Coll Cardiol., Apr. 1990, vol. 15 (5), p. 1104-1108.
Lung et al., “A Prospective Survey of Patients with Valvular Heart Disease in Europe: The Euro Heart Survey on Valvular Heart Disease”, Euro Heart Journal, Mar. 2003, vol. 24, pp. 1231-1243.
McBride et al “Aortic Valve Decalcification”, J Thorac Cardiovas-Surg, Jul. 1990, vol. 100, pp. 36-42.
Miller et al., “Lysis and Sonoporation of Epidermoid and Phagocytic Monolayer Cells by Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies”, Ultrasound in Med. & Biol., May 2007, vol. 27 (8), pp. 1107-1113.
Mohler, “Mechanisms of Aortic Valve Calcification”, Am J Cardiol, Dec. 2004, vol. 94 (11), pp. 1396-1402.
Otto et al., “Three-Year Outcome After Balloon Aortic Valvuloplasty. Insights into Prognosis of Valvular Aortic Stenosis”, Circulation, Feb. 1994, vol. 89, pp. 642-650.
Passik et al., “Temporal Changes in the Causes of Aortic Stenosis: A Surgical Pathologic Study of 646 Cases”, Mayo Clin Proc, Feb. 1987, vol. 62, pp. 19-123.
Quaden et al., “Percutaneous Aortic Valve Replacement: Resection Before Implantation”, Eur J Cardiothorac Surg, Jan. 2005, vol. 27, pp. 836-840.
Riebman et al., “New Concepts in the Management of Patients with Aortic Valve Disease”, Abstract, Valvular Heart Disease, JACC, Mar. 2004, p. 34A.
Rosenschein et al., “Percutaneous Transluminal Therapy of Occluded Saphenous Vein Grafts” Circulation, Jan. 1999, vol. 99, pp. 26-29.
Sakata et al., “Percutaneous Balloon Aortic Valvuloplasty: Antegrade Transseptal vs. Conventional Retrograde Transarterial Approach”, Catheter Cardiovasc Interv., Mar. 2005, vol. 64 (3), pp. 314-321.
Sasaki et al., “Scanning Electron Microscopy and Fourier Transformed Infrared Spectroscopy Analysis of Bone Removal Using Er:YAG and CO2 Lasers”, J Periodontol., Jun. 2002, vol. 73 (6), pp. 643-652.
Search Report and Written Opinion dated Dec. 10, 2012 for PCT Application No. PCT/US2012/043636.
Search Report and Written Opinion dated Dec. 6, 2016 for PCT Application No. PCT/US2016/047831.
International Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061215.
International Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061219.
International Search Report and Written Opinion dated Jul. 11, 2018 for PCT Application No. PCT/US2018/027990, 15 pages.
International Search Report and Written Opinion dated Jun. 28, 2018 for PCT Application No. PCT/US2018/027983, 15 pages.
International Search Report and Written Opinion dated Aug. 3, 2018 for PCT Application No. PCT/US2018/035086, 15 pages.
International Search Report and Written Opinion dated Aug. 9, 2018 for PCT Application No. PCT/US2018/035081, 11 pages.
Search Report and Written Opinion dated Mar. 2, 2015 for PCT Application No. PCT/US2014/029549.
Search Report and Written Opinion dated May 1, 2012 for PCT Application No. PCT/US2011/065627.
Search Report and Written Opinion dated May 22, 2007 for PCT Application No. PCT/US2005/044543.
Search Report and Written Opinion dated Oct. 20, 2014 for PCT Application No. PCT/US2014/038849.
Search Report and Written Opinion dated Sep. 4, 2014 for PCT Application No. PCT/US2014/014704.
The CoreValve System Medtronic, 2012, 4 Pages.
Van Den Brand et al., “Histological Changes in the Aortic Valve after Balloon Dilation: Evidence for a Delayed Healing Process”, Br Heart J, Jun. 1992, vol. 67, pp. 445-459.
Verdaasdonk et al., “The Mechanism of Action of the Ultrasonic Tissue Resectors Disclosed Using High-Speed and Thermal Imaging Techniques”, SPIE, Jan. 1999, vol. 3594, pp. 221-231.
Voelker et al., “Inoperative Valvuloplasty in Calcific Aortic Stenosis: a Study Comparing the Mechanism of a Novel Expandable Device with Conventional Balloon Dilation”, Am Heart J., Nov. 1991, vol. 122 (5), pp. 1327-1333.
Waller et al., “Catheter Balloon Valvuloplasty of Stenotic Aortic Valves. Part II: Balloon Valvuloplasty During Life Subsequent Tissue Examination”, Clin Cardiol., Nov. 1991, vol. 14 (11), pp. 924-930.
Wang, “Balloon Aortic Valvuloplasty”, Prog Cardiovasc Dis., Jul.-Aug. 1997, vol. 40 (1), pp. 27-36.
Wilson et al., “Elastography—The movement Begins”, Phys. Med. Biol., Jun. 2000, vol. 45, pp. 1409-1421.
Yock et al, “Catheter-Based Ultrasound Thrombolysis”, Circulation, Mar. 1997, vol. 95 (6), pp. 1411-1416.
Related Publications (1)
Number Date Country
20190192297 A1 Jun 2019 US
Provisional Applications (1)
Number Date Country
62329400 Apr 2016 US
Continuations (1)
Number Date Country
Parent 15489889 Apr 2017 US
Child 16293557 US